Stocks of Beam Therapeutics Inc. (NASDAQ:BEAM) traded higher last session on Wall Street, down -4.21% to $38.68.
BEAM stock price is now -11.13% away from the 50-day moving average and -18.64% away from the 200-day moving average. The market capitalization of the company currently stands at $2.78B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
With the price target enhanced from $61 to $66, BMO Capital Markets Upgraded its rating from Market Perform to Outperform for Beam Therapeutics Inc. (NASDAQ: BEAM). On December 13, 2022, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $62, while ‘BMO Capital Markets’ rates the stock as ‘Market Perform’.
In other news, Ciaramella Giuseppe, President & CSO sold 53,729 shares of the company’s stock on Jan 03. The stock was sold for $2,012,490 at an average price of $37.46. Upon completion of the transaction, the President & CSO now directly owns 95,962 shares in the company, valued at $3.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 12, President & CSO Ciaramella Giuseppe sold 51,015 shares of the business’s stock. A total of $2,178,229 was realized by selling the stock at an average price of $42.70. This leaves the insider owning 91,462 shares of the company worth $3.54 million. Insiders disposed of 3,285,986 shares of company stock worth roughly $127.1 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BEAM stock. A new stake in Beam Therapeutics Inc. shares was purchased by EVENTIDE ASSET MANAGEMENT, LLC during the first quarter worth $10,329,000. HOOD RIVER CAPITAL MANAGEMENT LLC invested $8,896,000 in shares of BEAM during the first quarter. In the first quarter, WOODLINE PARTNERS LP acquired a new stake in Beam Therapeutics Inc. valued at approximately $3,216,000. SECTORAL ASSET MANAGEMENT INC acquired a new stake in BEAM for approximately $2,541,000. AMERIPRISE FINANCIAL INC purchased a new stake in BEAM valued at around $2,190,000 in the second quarter. In total, there are 306 active investors with 87.10% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $41.07 for Beam Therapeutics Inc. (NASDAQ: BEAM). During the past 12 months, Beam Therapeutics Inc. has had a low of $27.77 and a high of $80.00. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 4.60, and a quick ratio of 4.60. The fifty day moving average price for BEAM is $43.52 and a two-hundred day moving average price translates $47.54 for the stock.
The latest earnings results from Beam Therapeutics Inc. (NASDAQ: BEAM) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.02, beating analysts’ expectations of -$1.08 by 0.06. This compares to -$0.42 EPS in the same period last year. The company reported revenue of $15.8 million for the quarter, compared to $0.76 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1970.64 percent. For the current quarter, analysts expect BEAM to generate $7.94M in revenue.
Beam Therapeutics Inc.(BEAM) Company Profile
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children’s Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
